Table 3.
Different AI-designed drugs that enter clinical trials
| Sl. No. | Drug | Clinical trials number | Phase | Organization/sponsor | Remark |
|---|---|---|---|---|---|
| 1. | REC-4881 | NCT05552755 | 1 and 2 | Recursion Pharmaceuticals Inc., USA |
Inhibitor component of mitogen-activated protein kinase kinase 1 and 2 for individual with familial adenomatous polyposis |
| 2. | BEN-2293 | NCT04737304 | 1 and 2 | BenevolentAI, UK |
It is an inhibitor of pan-tyrosine kinase inhibitor applies to patients who have atopic dermatitis (mild to moderate) |
| 3. | RLY-4008 | NCT04526106 | 1 and 2 | Relay Therapeutics, USA | The inhibitor of fibroblast growth factor receptor 2 used against in the patients with unresectable or metastatic cholangiocarcinoma and other solid tumors |
| 4. | BEN-8744 | NCT06118385 | 1 | BenevolentAI, UK |
The phosphodiesterase 10 inhibitor for treating inflammatory bowel diseases such as ulcerative colitis |
| 5. | REC-2282 | NCT05130866 | 2 and 3 | Recursion Pharmaceuticals Inc., USA | The histone deacetylase inhibitor used for in patients with progressive NF2-mutated meningiomas |
| 6. | INS018_055 | NCT05975983 | 2 | In Silico Medicine Hong Kong Limited, China | Consider as small molecules inhibitor of adults with idiopathic pulmonary fibrosis |
| 7. | REC-994 | NCT05085561 | 2 | Recursion Pharmaceuticals Inc., USA |
The superoxide scavenger molecule used against symptomatic cerebral cavernous malformation |
| 8. | EXS-21546 | NCT05920408 | 1 and 2 | Exscientia AI Limited, Scotland |
Adenosine A2A receptor antagonist molecule used against advanced solid tumors carrying high adenosine signatures |
| 9. | GTAEXS617 | NCT05985655 | 1 and 2 | Exscientia AI Limited, Scotland |
The CD4/CDK6 inhibitor, used for the treatment of advanced solid tumors |
| 10. | ISM3312 | CTR20230768 | 2 | Insilico Medicine, China |
Used for the treatment of coronavirus disease 2019 patients as 3CL protease inhibitor compound |
| 11. | NDI-010976/GS-0976 |
NCT02876796, NCT02856555, NCT02891408, NCT03987074 |
1 and 2 | Gilead Sciences, USA |
The oral dose administration in against of nonalcoholic fatty liver disease |
| 12. | OPL-0401 | NCT05393284 | 2 | Valo Health, Inc, USA |
The drug used for patients with diabetes mellitus with non-proliferative diabetic retinopathy or mild proliferative diabetes retinopathy with or without diabetic macular edema |
| 13. | ISM3091 | NCT05932862 | 1 | Exelixis, USA |
The combination therapy with olaparib in patients with advanced solid tumors |
| 14. | RLY-1971/RG-6433 | NCT04252339 | 1 | Hoffmann-La Roche, Switzerland |
Used as highly potent and selective SHP2 inhibitor, for advanced or metastatic solid tumors |
| 15. | RLY-2608 | NCT05216432 | 1 | Relay Therapeutics, Inc. USA |
The single agent in advanced solid tumor patients and in combination with fulvestrant in patients with advanced breast cancer |
| 16. | ANPA-0073 | ACTRN12621000644864 | 1 | Structure Therapeutics, USA |
The testing single incremental doses of oral capsules used for patient having pulmonary arterial hypertension, idiopathic pulmonary fibrosis |
| 17. | PHI-101 |
NCT04842370 NCT04678102 |
1 | Seoul National University Hospital, South Korea |
The PHI-101, and novel FLT3 inhibitor in the treatment of relapsed or refractory acute myeloid leukemia for patients who have received standard therapy |
| 18. | SGR-1505 | NCT05544019 | 1 | Schrödinger, Inc. USA |
The oral inhibitor of MALT1 used against for the non-Hodgkin’s lymphoma |
| 19. | OPL-0301 | NCT05327855 | 2 | Valo Health, Inc, USA |
The supportive impromevnt drug used for the patients having post-myocardial infarction left ventricular dysfunction |
| 20. | GSBR-1290 | NCT05762471 | 1 and 2 | Gasherbrum bio inc. USA |
This drug used for the patients having overweight/obesity and type 2 diabetes mellitus on metformin |